Curate Capital has announced its latest portfolio company. Photo courtesy of Curate Capital

A Houston investor has led the latest funding round for a New York-based tech company focused on democratizing access to the global supply chain through its turn key solution for ethical manufacturing.

Curate Capital, a fund focused on early-stage, female-founded companies, led TO THE MARKET's $5 million series A round, the firms announced this week. TO THE MARKET has created a technology platform that provides makers from around the world with the opportunity of fair pay, safe work, and economic empowerment. After several years of growth, the company now represents a syndicated supply chain of over 200 makers in more than 50 countries.

"We are honored to join forces with TO THE MARKET to amplify further their work powering the ethical supply chain," says Carrie Colbert, Curate Capital founding and general partner, in a news release. "At Curate Capital, we are industry-agnostic, but rather look across industry boundaries to identify the very best companies being built by women for the benefit of other women. Making an investment in the ESG space has been a high priority for us, and no one is better suited to build a successful company in this realm than Jane Mosbacher Morris. She is uniquely suited and qualified to transform retail manufacturing."

Several other investors supported the round, including Working Capital Fund, Spouting Rock, Forward Ventures, Belle Fund, Knightsgate Ventures, and a number of angel investors.

Mosbacher Morris, who originally started her career in the state department in counterterrorism, founded the company in 2016. She's a Houston native and still has family locally.

"I am thrilled that Curate Capital is leading the round because of their deep expertise in scaling women-focused businesses," says Mosbacher Morris in the release. "Women are the majority of garment workers, the majority of buyers at retail organizations, and the majority of consumers. But typically they are not the factory owners, the company CEOs, or the investors on the cap table. It's great to be a part of changing that dynamic."

The company will use the funds to support its growth. Last year, Mosbacher Morris was named one of 2020's Heroes Of The Pandemic for TO THE MARKET's swift pivot to manufacturing PPE for healthcare workers, according to the release.

Curate Capital was founded in 2020 by Colbert and Mark Latham. The firm, and its initial $10 million fund, is focused on funding early-stage, female-founded companies. The company also recently announced an investment in Houston startup Ampersand's pre-seed round.

Colbert recently joined the Houston Innovators Podcast to discuss her fund. Listen to the episode below.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”